American School of Oncology

First-line Metastatic Colon Cancer

Other Professions Click Here to Continue

Release Date: October 14, 2003

Course Overview:

This case module discusses first-line therapies for First-line Metastatic Colon Cancer. It provides a review of research findings on various treatments of First-line Metastatic Colon Cancer, and concludes with recommendations for treatment and the need for further exploration.

This activity will be valid until October 14, 2004.

Objectives:

At the completion of this course, physicians will be better able to:

Discuss research findings concerning First-line Metastatic Colon Cancer.
Describe current treatment options for First-line Metastatic Colon Cancer.

Faculty:

Howard S. Hochster, MD
Professor of Medicine
New York University School of Medicine
New York, New York

According to the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education, the faculty has been asked to disclose significant financial arrangements related to the content of this continuing medical education program. Dr. Hochster participates in formal advisory activities and specific research activities supported by Sanofi-Synthelabo Inc, Eli Lilly, and AstraZeneca.

Target Audience:

This educational activity has been designed to meet the educational needs of oncologists.

Accreditation Information:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Alabama School of Medicine and the Network for Oncology Communication and Research. The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Alabama School of Medicine designates this educational activity for a maximum of 0.25 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

Time to completion:

It will take 0.25 hours to complete this course.

Commercial Support:

Support for this program has been provided by an unrestricted educational grant from Sanofi-Synthelabo Inc.

Participation in the course:

This course is offered in a case format online. Successful completion of the course and course evaluation will lead to an online certificate for 0.25 Category 1 credits that can be printed for your records. To receive credit, the course must be completed before October 14, 2004.

Physicians Click Here To Continue

Other Professions Click Here to Continue

The information provided by this service is intended for use as continuing education only. The user assumes full responsibility and all risks for the appropriate use of the information contained or provided by this NOCR service. The opinions of the expert discussant(s) expressed in this service are not necessarily those of the Network for Medical Communication & Research, LLC (NMCR). NMCR makes no warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, product, or process disclosed.



	First-line Metastatic Colon Cancer Physicians Click Here To Continue Other Professions Click Here to Continue Release Date: October 14, 2003 Course Overview: This case module discusses first-line therapies for First-line Metastatic Colon Cancer. It provides a review of research findings on various treatments of First-line Metastatic Colon Cancer, and concludes with recommendations for treatment and the need for further exploration. This activity will be valid until October 14, 2004. Objectives: At the completion of this course, physicians will be better able to: Discuss research findings concerning First-line Metastatic Colon Cancer. Describe current treatment options for First-line Metastatic Colon Cancer. Faculty: Howard S. Hochster, MD Professor of Medicine New York University School of Medicine New York, New York According to the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education, the faculty has been asked to disclose significant financial arrangements related to the content of this continuing medical education program. Dr. Hochster participates in formal advisory activities and specific research activities supported by Sanofi-Synthelabo Inc, Eli Lilly, and AstraZeneca. Target Audience: This educational activity has been designed to meet the educational needs of oncologists. Accreditation Information: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Alabama School of Medicine and the Network for Oncology Communication and Research. The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Alabama School of Medicine designates this educational activity for a maximum of 0.25 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity. Time to completion: It will take 0.25 hours to complete this course. Commercial Support: Support for this program has been provided by an unrestricted educational grant from Sanofi-Synthelabo Inc. Participation in the course: This course is offered in a case format online. Successful completion of the course and course evaluation will lead to an online certificate for 0.25 Category 1 credits that can be printed for your records. To receive credit, the course must be completed before October 14, 2004. Physicians Click Here To Continue Other Professions Click Here to Continue The information provided by this service is intended for use as continuing education only. The user assumes full responsibility and all risks for the appropriate use of the information contained or provided by this NOCR service. The opinions of the expert discussant(s) expressed in this service are not necessarily those of the Network for Medical Communication & Research, LLC (NMCR). NMCR makes no warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, product, or process disclosed. Network for Oncology Communication & Research (NOCR) is a division of Network for Medical Communication and Research, LLC (NMCR).